Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression.

ABSTRACT: More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a potentially promising rapid-acting therapy for treatment-resistant depression (TRD). However, few studies have examined the safety, tolerability and efficacy of ketamine therapy for older adults with late-life TRD (LL-TRD). This study uses an adaptive randomization design to test the safety, tolerability, efficacy, and durability of three distinct, single sub-anesthetic doses of intravenous (IV) ketamine versus a single dose of active placebo (midazolam) in older depressed veterans. As the study p

SUBMITTER: O'Brien B 

PROVIDER: S-EPMC6727003 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature